Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-3489

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-3489). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a prescription medicine called Losartan Potassium. There are 30 tablets in the quantity. The recommended storage temperature range is from 20-25°C (88-77°F). It is manufactured by Sclce in Cranbury, NJ with Lot # not available. The NDC number for the product is 70518-3489-00 and the Source NDC is 43547-0360-11. This medication should be kept out of the reach of children. For usage directions, please refer to the Package Insert. Repackaging is done by RemedyRepack Inc. located in Indiana, PA 15701.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This text appears to be a comparison between two medications, Atenolol and Losartan Potassium, for a primary endpoint related to patient outcomes. The information provided shows an adjusted risk reduction of 13% with a p-value of 0.021. The timeline of the study is also shown, with a duration of 66 months broken down into individual months.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

The text is describing a comparison between two medications, Atenolol and Losartan Potassium. It states that Losartan Potassium has an adjusted risk reduction of 25% with a p-value of 0.001. The text also provides a table indicating the percentage of patients with fatal/non-fatal strokes at each study month, ranging from 6 to 66 months.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

This is a table displaying the primary endpoint events within demographic subgroups for patients using Losartan Potassium and Atenolol. The primary composite stroke (fatal/non-fatal) occurrence rate is given as a percentage along with the hazard ratio (95% CI) for each demographic subgroup. The subgroup categories include age, gender, race, ISH, diabetes, and history of CVD. The table also notes that the symbols are proportional to sample size, and the hazard ratios have been adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This appears to be a graph or table that shows the percentage of patients with an event over time (measured in months) for two treatments, Losartan Potassium and Placebo. The table also states that the Risk Reduction for Losartan Potassium compared to Placebo is 16.1%, and the p-value for this result is 0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.